{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T19:51:52Z","timestamp":1782503512052,"version":"3.54.5"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.intimp.2023.111072","type":"journal-article","created":{"date-parts":[[2023,11,24]],"date-time":"2023-11-24T12:52:46Z","timestamp":1700830366000},"page":"111072","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Predictions based on inflammatory cytokine profiling of Egyptian COVID-19 with 2 potential therapeutic effects of certain marine-derived compounds"],"prefix":"10.1016","volume":"126","author":[{"given":"Mohamed E.","family":"Elnosary","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Attia","family":"Shreadah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed L.","family":"Ashour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5560-0674","authenticated-orcid":false,"given":"Asmaa","family":"Nabil-Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2023.111072_b0005","doi-asserted-by":"crossref","unstructured":"M. Cascella, M. Rajnik, A. Aleem, S.C. Dulebohn, R. Di Napoli, Features, Evaluation, and Treatment of Coronavirus (COVID-19), in: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan\u2013. PMID: 32150360. A.E. Adegboyega, T.O. Johnson, S. Omale, Computational modeling of the pharmacological actions of some antiviral agents against SARS-CoV-2, Data Sci. COVID-19 (2021) 467\u2013482 Epub 2021 May 21. PMCID: PMC8137999, doi: 10.1016\/B978-0-12-824536-1.00018-6.","DOI":"10.1016\/B978-0-12-824536-1.00018-6"},{"key":"10.1016\/j.intimp.2023.111072_b0010","doi-asserted-by":"crossref","first-page":"04","DOI":"10.1186\/s12939-020-01218-z","article-title":"Health equity and COVID-19: global perspectives","volume":"19","author":"Shadmi","year":"2020","journal-title":"Int J Equity Health"},{"issue":"1","key":"10.1016\/j.intimp.2023.111072_b0015","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10787-020-00773-9","article-title":"The Role and Therapeutic Potential of NF-kappa-B Pathway in Severe COVID-19 Patients","volume":"29","author":"Hariharan","year":"2021","journal-title":"Inflammopharmacology"},{"issue":"15","key":"10.1016\/j.intimp.2023.111072_b0020","article-title":"The Role of NF-\u03baB Triggered Inflammation in Cerebral Ischemia","volume":"10","author":"Jover-Mengual","year":"2021","journal-title":"Front Cell Neurosci."},{"key":"10.1016\/j.intimp.2023.111072_b0025","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s43055-021-00484-3","article-title":"MBI Ghonimy Post-COVID-19 pneumonia lung fibrosis: a worrisome sequelae in surviving patients","volume":"52","author":"Ali","year":"2021","journal-title":"Egypt J Radiol Nucl Med"},{"issue":"4","key":"10.1016\/j.intimp.2023.111072_b0030","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.cell.2021.01.007","article-title":"Adaptive immunity to SARS-CoV-2 and COVID-19","volume":"184","author":"Sette","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.intimp.2023.111072_b0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.112420","article-title":"Molecular pathways involved in COVID-19 and potential pathway-based therapeutic targets","volume":"145","author":"Farahani","year":"2022","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.intimp.2023.111072_b0040","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.amsu.2020.06.010","article-title":"Is the lockdown important to prevent the COVID-19 pandemic? Effects on psychology, environment, and economy-perspective","volume":"56","author":"Atalan","year":"2020","journal-title":"Ann Med Surg (Lond)"},{"key":"10.1016\/j.intimp.2023.111072_b0045","doi-asserted-by":"crossref","unstructured":"D.M. Kern, B. Sorum, S.S. Mali, C.M. Hoel, S. Sridharan, J.P. Remis, D.B. Toso, A. Kotecha, D.M. Bautista, S.G. Brohawn, Cryo-EM structure of the SARS-CoV-2 3a ion channel in lipid nanodiscs, 2021. bioRxiv [Preprint] 2020.06.17.156554. doi: 10.1101\/2020.06.17.156554. Update in: Nat Struct Mol Biol. 2021 Jul;28(7):573-582. PMID: 32587976; PMCID: PMC7310636.","DOI":"10.1038\/s41594-021-00619-0"},{"key":"10.1016\/j.intimp.2023.111072_b0050","doi-asserted-by":"crossref","unstructured":"M-H Lin, S-C Chang, Y-CChiu,B-CJiang, T-HWu, C-HHsu Structural, Biophysical, and Biochemical Elucidation of the SARS-CoV-2 Nonstructural Protein 3 Macro Domain,ACS Infectious Diseases6(11) (2020) 2970-2978, doi: 10.1021\/acsinfecdis.0c00441.","DOI":"10.1021\/acsinfecdis.0c00441"},{"key":"10.1016\/j.intimp.2023.111072_b0055","doi-asserted-by":"crossref","unstructured":"McMillan D, Martinez-Fleites C, Porter, J. Fox 3rd D, Davis R, Mori P, Ceska T, Carrington B, Lawson A, Bourne T, O\u2019Connell J (2021) Structural insights into the disruption of TNF-TNFR1 signaling by small molecules stabilizing a distorted TNF. Nat Commun 12, 582. Doi: 10.1038\/s41467-020-20828-3.","DOI":"10.1038\/s41467-020-20828-3"},{"key":"10.1016\/j.intimp.2023.111072_b0060","doi-asserted-by":"crossref","unstructured":"Liu J, Sudom A, Min X, Cao Z, Gao X, Ayres M, Lee F, Cao P, Johnstone S, Plotnikova O, Walker N, Chen G, Wang Z (2012) Structure of the nuclear factor \u03baB-inducing kinase (NIK) kinase domain reveals a constitutively active conformation. J Biol Chem 287(33):27326-34. doi: 10.1074\/jbc.M112.366658. Epub 2012 Jun 20. PMID: 22718757; PMCID: PMC3431628.","DOI":"10.1074\/jbc.M112.366658"},{"issue":"2","key":"10.1016\/j.intimp.2023.111072_b0065","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J Comput Chem"},{"issue":"7","key":"10.1016\/j.intimp.2023.111072_b0070","doi-asserted-by":"crossref","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules","volume":"3","author":"Daina","year":"2017","journal-title":"Sci Rep."},{"key":"10.1016\/j.intimp.2023.111072_b0075","doi-asserted-by":"crossref","unstructured":"Chen X, Wang T, Song L, Liu X (2019) Activation of multiple Toll-like receptors serves different roles in sepsis-induced acute lung injury. Exp Ther Med 18(1):443-450. doi: 10.3892\/etm.2019.7599. Epub 2019 May 23. PMID: 31258682; PMCID: PMC6566018.","DOI":"10.3892\/etm.2019.7599"},{"key":"10.1016\/j.intimp.2023.111072_b0080","doi-asserted-by":"crossref","unstructured":"Vatansever HS, Becer E. Relationship between IL-6 and COVID-19: to be considered during treatment. Future Virol. 2020 Dec:10.2217\/fvl-2020-0168. doi: 10.2217\/fvl-2020-0168. Epub 2020 Dec 24. PMCID: PMC7780788.","DOI":"10.2217\/fvl-2020-0168"},{"key":"10.1016\/j.intimp.2023.111072_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.micpath.2021.104799","article-title":"The proinflammatory cytokines in COVID-19 pathogenesis: What goes wrong?","volume":"153","author":"Darif","year":"2021","journal-title":"Microb Pathog"},{"key":"10.1016\/j.intimp.2023.111072_b0090","doi-asserted-by":"crossref","unstructured":"Diao B, Wang C, Tan Y, Chen X, Liu Y, Ning L, Chen L, Li M, Liu Y, Wang G, Yuan Z, Feng Z, Zhang Y, Wu Y, Chen Y (2020) Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). MedRxiv (Epub ahead of print). [PMC free article] [PubMed] [Google Scholar].","DOI":"10.3389\/fimmu.2020.00827"},{"key":"10.1016\/j.intimp.2023.111072_b0095","unstructured":"C Huang, YWang, XLi, LRen, JZhao, YHu, LZhang, et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan China, Lancet10223(2020) 497\u2013506."},{"issue":"9","key":"10.1016\/j.intimp.2023.111072_b0100","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/cbin.11403","article-title":"Lymphopenia in COVID-19: Therapeutic opportunities","volume":"44","author":"Fathi","year":"2020","journal-title":"Cell Biol Int."},{"key":"10.1016\/j.intimp.2023.111072_b0105","doi-asserted-by":"crossref","unstructured":"AA Rabaan, SH Al-Ahmed, J Muhammad, A Khan, AA Sule, R Tirupathi, AA Mutair, S Alhumaid, A Al-Omari, M Dhawan, R Tiwari, K Sharun, RK Mohapatra, S Mitra, M Bilal, SA Alyami,TB Emran, MAMoni, K Dhama, Role of Inflammatory Cytokines in COVID-19 Patients: A Review on Molecular Mechanisms, Immune Functions, Vaccines (Basel) 9(5) (2021) 436, doi: 10.3390\/vaccines9050436.","DOI":"10.3390\/vaccines9050436"},{"issue":"2","key":"10.1016\/j.intimp.2023.111072_b0110","doi-asserted-by":"crossref","DOI":"10.1111\/sji.13131","article-title":"COVID-19 immunopathology with emphasis on Th17 response and cell-based immunomodulation therapy: Potential targets and challenges","volume":"95","author":"Pourgholaminejad","year":"2022","journal-title":"Scand J Immunol"},{"key":"10.1016\/j.intimp.2023.111072_b0115","doi-asserted-by":"crossref","unstructured":"Kovalchuk A, Wang B, Li D, Rodriguez-Juarez R, Ilnytskyy S, Kovalchuk I, Kovalchuk O (2021) Fighting the storm: could novel anti-TNF\u03b1 and anti-IL-6 C. sativa cultivars tame cytokine storm in COVID-19? Aging (Albany NY)13(2):1571-1590. doi: 10.18632\/aging.202500. Epub 2021 Jan 19. PMID: 33465050; PMCID: PMC7880317.","DOI":"10.18632\/aging.202500"},{"issue":"8","key":"10.1016\/j.intimp.2023.111072_b0120","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1007\/s12035-021-02438-2","article-title":"The Effect of COVID-19 on NF-\u03baB and Neurological Manifestations of Disease","volume":"58","author":"Davies","year":"2021","journal-title":"Mol Neurobiol"},{"key":"10.1016\/j.intimp.2023.111072_b0125","doi-asserted-by":"crossref","unstructured":"DeDiego ML, Nieto-Torres JL, Regla-Nava JA, Jimenez-Guarde\u00f1o JM, Fernandez-Delgado R, Fett C, Casta\u00f1o-Rodriguez C, Perlman S, Enjuanes L (2014) Inhibition of NF-\u03baB-mediated Inflammation in severe acute respiratory syndrome coronavirus-infected mice increases survival. J Virol 88(2):913-24. doi: 10.1128\/JVI.02576-13. Epub 2013 Nov 6. PMID: 24198408; PMCID: PMC3911641.","DOI":"10.1128\/JVI.02576-13"},{"issue":"7","key":"10.1016\/j.intimp.2023.111072_b0130","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3389\/fcell.2019.00154","article-title":"What Is Nuclear Factor Kappa B (NF-\u03baB) Doing in and to the Mitochondrion?","volume":"7","author":"Albensi","year":"2019","journal-title":"Front Cell Dev Biol."},{"issue":"22","key":"10.1016\/j.intimp.2023.111072_b0135","doi-asserted-by":"crossref","first-page":"12486","DOI":"10.3390\/ijms222212486","article-title":"Natural Compound Resveratrol Attenuates TNF-Alpha-Induced Vascular Dysfunction in Mice and Human Endothelial Cells: The Involvement of the NF-\u03baB Signaling Pathway","volume":"22","author":"Nallasamy","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.intimp.2023.111072_b0140","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1002\/jmv.28000","article-title":"The deciphering of the immune cells and marker signature in COVID-19 pathogenesis: an update","volume":"94","author":"Jasim","year":"2022","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.intimp.2023.111072_b0145","doi-asserted-by":"crossref","unstructured":"Qazi BS, Tang K, Qazi A. Recent advances in underlying pathologies provide insight into interleukin-8 expression-mediated inflammation and angiogenesis. Int J Inflam. 2011;2011:908468. doi: 10.4061\/2011\/908468. Epub 2011 Dec 22. PMID: 22235381; PMCID: PMC3253461.","DOI":"10.4061\/2011\/908468"},{"key":"10.1016\/j.intimp.2023.111072_b0150","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1359-6101(01)00016-8","article-title":"Interleukin-8 and human cancer biology","volume":"12","author":"Xie","year":"2001","journal-title":"Cytokine Growth Factor Rev"},{"issue":"4","key":"10.1016\/j.intimp.2023.111072_b0155","article-title":"Analysis of cytokines in SARS-CoV-2 or COVID-19 patients in Erbil city","volume":"16","author":"Merza","year":"2021","journal-title":"Kurdistan Region of Iraq. PLoS One"},{"issue":"2022","key":"10.1016\/j.intimp.2023.111072_b0160","doi-asserted-by":"crossref","first-page":"2755246","DOI":"10.1155\/2022\/2755246","article-title":"Associations between Serum Interleukins (IL-1\u03b2, IL-2, IL-4, IL-6, IL-8, and IL-10) and Disease Severity of COVID-19: A Systematic Review and Meta-Analysis","volume":"30","author":"Chang","year":"2022","journal-title":"Biomed Res Int."},{"key":"10.1016\/j.intimp.2023.111072_b0165","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.570993","article-title":"Controlling Cytokine Storm Is Vital in COVID-19","volume":"11","author":"Tang","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.intimp.2023.111072_b0170","doi-asserted-by":"crossref","unstructured":"Gubernatorova EO, Gorshkova EA, Polinova AI, Drutskaya MS (2020) IL-6: Relevance for immunopathology of SARS-CoV-2. Cytokine Growth Factor Rev 53:13-24. doi: 10.1016\/j.cytogfr.2020.05.009. Epub 2020 May 20. PMID: 32475759; PMCID: PMC7237916.","DOI":"10.1016\/j.cytogfr.2020.05.009"},{"issue":"1","key":"10.1016\/j.intimp.2023.111072_b0175","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1080\/22221751.2020.1770129","article-title":"Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors","volume":"9","author":"Han","year":"2020","journal-title":"Emerg Microbes Infect"},{"key":"10.1016\/j.intimp.2023.111072_b0180","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.3389\/fimmu.2020.01949","article-title":"Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past","volume":"11","author":"Shah","year":"2020","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.intimp.2023.111072_b0185","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1080\/14787210.2021.1915129","article-title":"Cytokine storm associated coagulation complications in COVID-19 patients: Pathogenesis and Management","volume":"19","author":"Savla","year":"2021","journal-title":"Expert Rev Anti Infect Ther."},{"key":"10.1016\/j.intimp.2023.111072_b0190","article-title":"Cardiovascular Dysfunction in COVID-19: Association Between Endothelial Cell Injury and Lactate","volume":"13","author":"Yang","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.intimp.2023.111072_b0195","doi-asserted-by":"crossref","unstructured":"Prasad M, Leon M, Lerman LO, Lerman A (2021) Viral Endothelial Dysfunction: A Unifying Mechanism for COVID-19. Mayo Clin Proc (12):3099-3108. doi: 10.1016\/j.mayocp.2021.06.027. Epub 2021 Aug 19. PMID: 34863398; PMCID: PMC8373818.","DOI":"10.1016\/j.mayocp.2021.06.027"},{"issue":"13","key":"10.1016\/j.intimp.2023.111072_b0200","doi-asserted-by":"crossref","first-page":"737","DOI":"10.2147\/JIR.S276091","article-title":"Cytokine Response in SARS-CoV-2 Infection in the Elderly","volume":"20","author":"Sherwani","year":"2020","journal-title":"J Inflamm Res."},{"issue":"5","key":"10.1016\/j.intimp.2023.111072_b0205","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.healun.2020.03.012","article-title":"COVID-19 illness in native and immunosuppressed states: A clinical-therapeutic staging proposal","volume":"39","author":"Siddiqi","year":"2020","journal-title":"J Heart Lung Transplant."},{"key":"10.1016\/j.intimp.2023.111072_b0210","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.3389\/fimmu.2020.01708","article-title":"Cytokine Storm in COVID-19: The Current Evidence and Treatment Strategies","volume":"11","author":"Tang","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.intimp.2023.111072_b0215","doi-asserted-by":"crossref","DOI":"10.1177\/1753466620937175","article-title":"C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis","volume":"14","author":"Huang","year":"2020","journal-title":"Therapeutic Advances in Respiratory Disease"},{"key":"10.1016\/j.intimp.2023.111072_b0220","doi-asserted-by":"crossref","unstructured":"Beltr\u00e1n-Garc\u00eda J, Osca-Verdegal R, Pallard\u00f3 FV, Ferreres J, Rodr\u00edguez M, Mulet S, Ferrando-S\u00e1nchez C, Carbonell N, Garc\u00eda-Gim\u00e9nez JL. Sepsis and Coronavirus Disease 2019: Common Features and Anti-Inflammatory Therapeutic Approaches. Crit Care Med. 2020 Dec;48(12):1841-1844. doi: 10.1097\/CCM.0000000000004625. PMID: 32826431; PMCID: PMC7467034.","DOI":"10.1097\/CCM.0000000000004625"},{"key":"10.1016\/j.intimp.2023.111072_b0225","unstructured":"Wang L (2020) C-reactive protein levels in the early stage of COVID-19. Med. Mal. Infect. 2020 Mar 31 https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC7146693\/ [Internet]. [cited 2020 Apr 29]; Available from. S0399-077X(20)30086-X. [PMC free article] [PubMed] [Google Scholar]."},{"issue":"4","key":"10.1016\/j.intimp.2023.111072_b0230","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.728","article-title":"A systematic review and meta-analysis of abnormalities in hematological and biochemical markers among Bangladeshi COVID-19 cases","volume":"5","author":"Bhowmik","year":"2022","journal-title":"Health Sci Rep"},{"issue":"4","key":"10.1016\/j.intimp.2023.111072_b0235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0249346","article-title":"Khalil MAF (2021) Clinical characteristics of Egyptian male patients with COVID-19 acute respiratory distress syndrome","volume":"16","author":"Doghish","year":"2021","journal-title":"PLoS One."},{"key":"10.1016\/j.intimp.2023.111072_b0240","doi-asserted-by":"crossref","unstructured":"Urra JM, Cabrera CM, Porras L, R\u00f3denas I (2020) Selective CD8 cell reduction by SARS-CoV-2 is associated with a worse prognosis and systemic Inflammation in COVID-19 patients. Clin Immunol 217:108486. doi: 10.1016\/j.clim.2020.108486. Epub 2020 May 29. PMID: 32479985; PMCID: PMC7256549.","DOI":"10.1016\/j.clim.2020.108486"},{"issue":"15","key":"10.1016\/j.intimp.2023.111072_b0245","doi-asserted-by":"crossref","first-page":"7914","DOI":"10.3390\/ijms22157914","article-title":"Inflammatory Response in COVID-19 Patients Resulting from the Interaction of the Inflammasome and SARS-CoV-2","volume":"22","author":"Cheon","year":"2021","journal-title":"Int J Mol Sci."},{"key":"10.1016\/j.intimp.2023.111072_b0250","doi-asserted-by":"crossref","unstructured":"Mahroum N, Alghory A, Kiyak Z, Alwani A, Seida R, Alrais M, Shoenfeld Y (2022) Ferritin - from iron, through inflammation and autoimmunity, to COVID-19. J Autoimmun 126:102778. doi: 10.1016\/j.jaut.2021.102778. Epub 2021 Dec 6. PMID: 34883281; PMCID: PMC8647584.","DOI":"10.1016\/j.jaut.2021.102778"},{"issue":"12","key":"10.1016\/j.intimp.2023.111072_b0255","article-title":"Interleukin-6, CXCL10 and Infiltrating Macrophages in COVID-19-Related Cytokine Storm: Not One for All But All for One!","volume":"26","author":"Coperchini","year":"2021","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.intimp.2023.111072_b0260","doi-asserted-by":"crossref","first-page":"500","DOI":"10.5937\/jomb0-27554","article-title":"C-reactive protein as an early predictor of COVID-19 severity","volume":"39","author":"Ahnach","year":"2020","journal-title":"J Med Biochem"},{"key":"10.1016\/j.intimp.2023.111072_b0265","doi-asserted-by":"crossref","unstructured":"K. Aykac, Y. Ozsurekci, B.C.C. Yayla, S.L. Gurlevik, P.D. Oygar, N.B. Bolu, M.A. Tasar, F.S. Erdinc, G.T. Ertem, S. Neselioglu, O. Erel, A.B. Cengiz, M. Ceyhan, Oxidant and antioxidant balance in patients with COVID-19. Pediatr Pulmonol 56(9) (2021) 2803-2810. doi: 10.1002\/ppul.25549. Epub 2021 Jul 15. PMID: 34265172; PMCID: PMC8441878.","DOI":"10.1002\/ppul.25549"},{"key":"10.1016\/j.intimp.2023.111072_b0270","doi-asserted-by":"crossref","unstructured":"N. Yaghoubi, M. Youssefi, F. Jabbari Azad, F. Farzad, Z. Yavari, F. Zahedi Avval, Total antioxidant capacity as a marker of severity of COVID-19 infection: Possible prognostic and therapeutic clinical application. J Med Virol 94(4) (2022) 1558-1565. doi: 10.1002\/jmv.27500. Epub 2021 Dec 11. PMID: 34862613; PMCID: PMC9015601.","DOI":"10.1002\/jmv.27500"},{"key":"10.1016\/j.intimp.2023.111072_b0275","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbior.2020.100741","article-title":"Devilishly radical NETwork in COVID-19: oxidative stress, neutrophil extracellular traps (NETs), and T cell suppression","volume":"77","author":"Sch\u00f6nrich","year":"2020","journal-title":"Adv Biol Regul"},{"key":"10.1016\/j.intimp.2023.111072_b0280","doi-asserted-by":"crossref","unstructured":"M. Kermali, R.K. Khalsa, K. Pillai, Z. Ismail, A. Harky, The role of biomarkers in diagnosis of COVID-19 - A systematic review. Life Sci 254 (2020) 117788. doi: 10.1016\/j.lfs.2020.117788. Epub 2020 May 13. PMID: 32475810; PMCID: PMC7219356.","DOI":"10.1016\/j.lfs.2020.117788"},{"key":"10.1016\/j.intimp.2023.111072_b0285","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.583777","article-title":"Calming the Storm: Natural Immunosuppressants as Adjuvants to Target the Cytokine Storm in COVID-19","volume":"11","author":"Peter","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.intimp.2023.111072_b0290","doi-asserted-by":"crossref","unstructured":"J. Alijotas-Reig, E. Esteve-Valverde, C. Belizna, A. Selva-O'Callaghan, J. Pardos-Gea, A. Quintana, A. Mekinian, A. Anunciacion-Llunell, F. Mir\u00f3-Mur, Immunomodulatory therapy for the management of severe COVID-19. Beyond the antiviral therapy: A comprehensive review. Autoimmun Rev 19(7) (2020) 102569. doi: 10.1016\/j.autrev.2020.102569. Epub 2020 May 3. PMID: 32376394; PMCID: PMC7252146.","DOI":"10.1016\/j.autrev.2020.102569"},{"key":"10.1016\/j.intimp.2023.111072_b0295","doi-asserted-by":"crossref","unstructured":"M.O. Valenzuela-Almada, M.S. Putman, A. Duarte-Garc\u00eda, The protective effect of rheumatic disease agents in COVID-19. Best Pract Res Clin Rheumatol 35(1) (2021) 101659. doi: 10.1016\/j.berh.2021.101659. Epub 2021 Jan 13. PMID: 33526326; PMCID: PMC7833968.","DOI":"10.1016\/j.berh.2021.101659"},{"issue":"1","key":"10.1016\/j.intimp.2023.111072_b0300","doi-asserted-by":"crossref","first-page":"316","DOI":"10.7150\/thno.49713","article-title":"Immunopathogenesis and treatment of cytokine storm in COVID-19","volume":"11","author":"Kim","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.intimp.2023.111072_b0305","article-title":"Targeting TNF-\u03b1 for COVID-19: Recent Advanced and Controversies","volume":"10","author":"Guo","year":"2022","journal-title":"Front Public Health"},{"issue":"5","key":"10.1016\/j.intimp.2023.111072_b0310","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.3390\/ijms22052719","article-title":"The Role of Tumor Necrosis Factor Alpha (TNF-\u03b1) in Autoimmune Disease and Current TNF-\u03b1 Inhibitors in Therapeutics","volume":"22","author":"Jang","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.intimp.2023.111072_b0315","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.778913","article-title":"Corona Virus Disease 2019 (COVID-19) as a System-Level Infectious Disease With Distinct Sex Disparities","volume":"12","author":"Emadi-Baygi","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.intimp.2023.111072_b0320","doi-asserted-by":"crossref","unstructured":"S. Montazersaheb, S.M. Hosseiniyan Khatibi, M.S. Hejazi, V. Tarhriz, A. Farjami, F.G.Sorbeni, R. Farahzadi, Ghasemnejad T(2022) COVID-19 infection: an overview on cytokine storm and related interventions, Virol J 19; 92. Doi: 10.1186\/s12985-022-01814-1.","DOI":"10.1186\/s12985-022-01814-1"},{"key":"10.1016\/j.intimp.2023.111072_b0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108448","article-title":"COVID-19: Immunology and treatment options","volume":"215","author":"Felsenstein","year":"2020","journal-title":"Clin Immunol"},{"key":"10.1016\/j.intimp.2023.111072_b0330","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s41232-020-00146-3","article-title":"How COVID-19 induces cytokine storm with high mortality","volume":"40","author":"Hojyo","year":"2020","journal-title":"Inflamm Regener"},{"key":"10.1016\/j.intimp.2023.111072_b0335","doi-asserted-by":"crossref","unstructured":"N. Iqbal, N. Iqbal, Imatinib: a breakthrough of targeted therapy in cancer. Chemother Res Pract 2014 (2014) 357027. doi: 10.1155\/2014\/357027. Epub 2014 May 19. PMID: 24963404; PMCID: PMC4055302.","DOI":"10.1155\/2014\/357027"},{"key":"#cr-split#-10.1016\/j.intimp.2023.111072_b0340.1","unstructured":"J.M. Sanders, M.L. Monogue, T.Z. Jodlowski, J.B. Cutrell, Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review. JAMA 323"},{"key":"#cr-split#-10.1016\/j.intimp.2023.111072_b0340.2","doi-asserted-by":"crossref","unstructured":"(18) (2020) 1824-1836. doi: 10.1001\/jama.2020.6019.","DOI":"10.1001\/jama.2020.6019"},{"issue":"3","key":"10.1016\/j.intimp.2023.111072_b0345","doi-asserted-by":"crossref","first-page":"e00299","DOI":"10.1128\/CMR.00299-20","article-title":"Critical Determinants of Cytokine Storm and Type I Interferon Response in COVID-19 Pathogenesis","volume":"34","author":"Ramasamy","year":"2021","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.intimp.2023.111072_b0350","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.3389\/fimmu.2020.01949","article-title":"Overview of Immune Response During SARS-CoV-2 Infection: Lessons From the Past","volume":"11","author":"Shah","year":"2020","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.intimp.2023.111072_b0355","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1021\/acs.jmedchem.1c00335","article-title":"Kinases as Potential Therapeutic Targets for Anti-coronaviral Therapy","volume":"65","author":"Pillaiyar","year":"2022","journal-title":"J Med Chem"},{"issue":"23","key":"10.1016\/j.intimp.2023.111072_b0360","doi-asserted-by":"crossref","first-page":"6008","DOI":"10.3390\/ijms20236008","article-title":"Cytokines in Inflammatory Disease","volume":"20","author":"Kany","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.intimp.2023.111072_b0365","doi-asserted-by":"crossref","unstructured":"M. Soy, G. Keser, P. Atag\u00fcnd\u00fcz, F. Tabak, I. Atag\u00fcnd\u00fcz, S. Kayhan, Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment. Clin Rheumatol 39(7) (2020) 2085-2094. doi: 10.1007\/s10067-020-05190-5. Epub 2020 May 30. PMID: 32474885; PMCID: PMC7260446.","DOI":"10.1007\/s10067-020-05190-5"},{"key":"10.1016\/j.intimp.2023.111072_b0370","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.806568","article-title":"Kinase Inhibitors as Potential Therapeutic Agents in the Treatment of COVID-19","volume":"13","author":"Naik","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.intimp.2023.111072_b0375","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s12943-018-0804-2","article-title":"Vasantha Rupasinghe HP (2018) Kinase-targeted cancer therapies: progress, challenges and future directions","volume":"17","author":"Bhullar","year":"2018","journal-title":"Mol Cancer"},{"issue":"18","key":"10.1016\/j.intimp.2023.111072_b0380","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1007\/s40265-017-0830-1","article-title":"Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies","volume":"77","author":"Dyall","year":"2017","journal-title":"Drugs"},{"issue":"19","key":"10.1016\/j.intimp.2023.111072_b0385","doi-asserted-by":"crossref","first-page":"8924","DOI":"10.1128\/JVI.01429-16","article-title":"Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion","volume":"90","author":"Coleman","year":"2016","journal-title":"J Virol"},{"key":"10.1016\/j.intimp.2023.111072_b0390","doi-asserted-by":"crossref","unstructured":"V. Cagno, G. Magliocco, C. Tapparel, Y. Daali, The tyrosine kinase inhibitor nilotinib inhibits SARS-CoV-2 in vitro. Basic Clin Pharmacol Toxicol 128(4) (2021) 621-624. doi: 10.1111\/bcpt.13537. Epub 2020 Dec 4. PMID: 33232578; PMCID: PMC7753569.","DOI":"10.1111\/bcpt.13537"},{"issue":"1","key":"10.1016\/j.intimp.2023.111072_b0395","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40203-020-00058-7","article-title":"Are losartan and Imatinib effective against SARS-CoV-2 pathogenesis? A pathophysiologic-based in silico study","volume":"9","author":"Nejat","year":"2020","journal-title":"In Silico Pharmacol"},{"key":"10.1016\/j.intimp.2023.111072_b0400","doi-asserted-by":"crossref","unstructured":"D. Bernal-Bello, B. Jaenes-Barrios, A. Morales-Ortega, J.M. Ruiz-Giardin, V. Garc\u00eda-Berm\u00fadez, B. Frutos-P\u00e9rez, A.I. Farf\u00e1n-Sedano, C. de Ancos-Aracil, F. Bermejo, M. Garc\u00eda-Gil, A. Zapatero-Gaviria, J.V. San Mart\u00edn-L\u00f3pez, Imatinib might constitute a treatment option for lung involvement in COVID-19. Autoimmun Rev 19(7) (2020) 102565. doi: 10.1016\/j.autrev.2020.102565. Epub 2020 May 3. PMID: 32376403; PMCID: PMC7252139.","DOI":"10.1016\/j.autrev.2020.102565"},{"key":"10.1016\/j.intimp.2023.111072_b0405","doi-asserted-by":"crossref","unstructured":"C.P. Gomes, D.E. Fernandes, F. Casimiro, G.F. da Mata, M.T. Passos, P. Varela, G. Mastroianni-Kirsztajn, J.B. Pesquero, L. Cathepsin, In COVID-19: From Pharmacological Evidences to Genetics. Front Cell Infect Microbiol 10 (2020) 589505. doi: 10.3389\/fcimb.2020.589505. PMID: 33364201; PMCID: PMC7753008.","DOI":"10.3389\/fcimb.2020.589505"},{"key":"10.1016\/j.intimp.2023.111072_b0410","doi-asserted-by":"crossref","unstructured":"R. Strobelt, J. Adler, N. Paran, Y. Yahalom-Ronen, S. Melamed, B. Politi, Z. Shulman, D. Schmiedel, Y. Shaul, Imatinib inhibits SARS-CoV-2 infection by an off-target-mechanism. Sci Rep 12(1) (2022) 5758. doi: 10.1038\/s41598-022-09664-1. PMID: 35388061; PMCID: PMC8984672.","DOI":"10.1038\/s41598-022-09664-1"},{"key":"10.1016\/j.intimp.2023.111072_b0415","doi-asserted-by":"crossref","unstructured":"A.E. Adegboyega, T.O. Johnson, S. Omale, Computational modeling of the pharmacological actions of some antiviral agents against SARS-CoV-2. Data Science for COVID-19 (2021) 467\u201382. doi: 10.1016\/B978-0-12-824536-1.00018-6. Epub 2021 May 21. PMCID: PMC8137999.","DOI":"10.1016\/B978-0-12-824536-1.00018-6"},{"issue":"10","key":"10.1016\/j.intimp.2023.111072_b0420","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1080\/07391102.2020.1769733","article-title":"Marine natural compounds as potents inhibitors against the main protease of SARS-CoV-2-a molecular dynamic study","volume":"39","author":"Khan","year":"2021","journal-title":"J Biomol Struct Dyn"},{"issue":"9","key":"10.1016\/j.intimp.2023.111072_b0425","doi-asserted-by":"crossref","first-page":"879","DOI":"10.2165\/00003088-200544090-00001","article-title":"Clinical pharmacokinetics of Imatinib","volume":"44","author":"Peng","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.intimp.2023.111072_b0430","doi-asserted-by":"crossref","unstructured":"M. Henkes, H. van der Kuip, W.E. Aulitzky, Therapeutic options for chronic myeloid leukemia: focus on Imatinib (Glivec, Gleevectrade mark). Ther Clin Risk Manag 4(1) (2008) 163-87. PMID: 18728706; PMCID: PMC2503652.","DOI":"10.2147\/TCRM.S1527"}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692301398X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156757692301398X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T18:08:22Z","timestamp":1761588502000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156757692301398X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":87,"alternative-id":["S156757692301398X"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2023.111072","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predictions based on inflammatory cytokine profiling of Egyptian COVID-19 with 2 potential therapeutic effects of certain marine-derived compounds","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2023.111072","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"111072"}}